OpenBiome vs Amgen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cambridge MA YC W20 nonprofit FMT distributor that served 1,000+ hospitals for C. diff treatment; suspended distribution Dec 2024 after FDA enforcement discretion ended; submitted IND Phase 2 Nov 2024 — microbiome therapeutics regulatory transition.
About
OpenBiome is a Cambridge, Massachusetts-based nonprofit health research organization — backed by Y Combinator (W20) — that operated as the largest distributor of fecal microbiota transplant (FMT) products in the United States for over a decade, providing investigational FMT therapy to thousands of patients with recurrent Clostridioides difficile (C. diff) infection while accelerating research on human microbiome therapeutics. Founded in 2012, OpenBiome suspended FMT distribution as of December 31, 2024, following FDA regulatory changes that ended enforcement discretion for investigational FMT, and submitted an IND Phase 2 protocol application in November 2024 to pursue the FDA-approved clinical pathway for continued microbiome therapeutic development.
Amgen (AMGN) reported $33.4B revenue in FY2024, up 19% YoY (post-Horizon acquisition). Top-5 global biotech. 10+ blockbuster drugs. ~24,000 employees. HQ: Thousand Oaks, CA. Market cap ~$130B.
About
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologics and brought landmark medicines including Epogen, Neupogen, and Enbrel to market. The company reported revenues of $33.4B in FY2024, up 19% year-over-year, boosted by the transformational $28B acquisition of Horizon Therapeutics in October 2023.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.